Type “Spravato vs ketamine” into a search engine, and you’ll find dozens of articles insisting one is better than the other. The reality is far less dramatic. These treatments come from the same medication family, yet they’re prescribed differently, studied differently, and may be appropriate for different people. Before comparing effectiveness, it helps to understand what you’re actually comparing.
What Is the Difference Between Esketamine and Ketamine?
People often use the names interchangeably, which isn’t surprising. The medications are closely related, and both have become part of the conversation around treating depression when standard medications haven’t helped enough.
The distinction starts at the molecular level.
Ketamine contains two mirror-image molecules. Esketamine is one of them. Scientists isolated that molecule, studied it extensively, and eventually developed it into the prescription medication sold as Spravato.
That’s the basic difference between esketamine and ketamine.
The comparison between esketamine vs ketamine doesn’t end there, though. One medication earned FDA approval for specific depressive disorders after large clinical trials. The other is still commonly prescribed off-label for depression, despite having decades of medical use as an anesthetic.
So while the names sound similar, the clinical pathway for each treatment looks quite different.
Is Spravato the Same as Ketamine?
Not quite.
If someone tells you they’re receiving ketamine therapy, it doesn’t automatically mean they’re receiving Spravato. And if they’re receiving Spravato, it doesn’t mean every ketamine clinic offers the same experience.
Spravato esketamine treatment is available only through certified treatment centers. It’s administered as a nasal spray, and every session includes a period of observation before the patient leaves. That monitoring isn’t just a formality. Temporary side effects, including sleepiness, dizziness, dissociation, or changes in blood pressure, can happen during treatment.
Ketamine for depression usually follows a different route. Most clinics administer it through an IV infusion, although protocols vary. Some patients receive a series of ketamine infusions over several weeks, with follow-up visits depending on how they’re responding.
That difference in delivery is often one of the first practical distinctions patients notice.
Is Esketamine Weaker Than Ketamine?
This question comes up more often than you might expect.
People hear that Spravato contains only part of the ketamine molecule and naturally wonder, is esketamine weaker than ketamine?
The comparison isn’t that simple.
Strength isn’t really the deciding factor in psychiatric treatment. A medication can be highly effective without being “stronger,” just as a higher dose doesn’t automatically produce better results.
Spravato was developed to target depression in a specific way and was evaluated for people living with treatment-resistant depression. Ketamine has its own growing body of research, particularly through IV ketamine programs, but the two treatments aren’t interchangeable.
Your previous response to traditional antidepressants, your diagnosis, current symptoms, medical history, and even other medications all influence which option your provider may recommend.
Sometimes the better question isn’t which treatment is stronger.
It’s which one has the strongest evidence for your situation.
Does the Treatment Experience Feel Different?
Most people spend a lot of time comparing medications. Fewer stop to ask what treatment day actually looks like.
With Spravato esketamine, appointments happen in certified clinical settings. The medication is taken as a nasal spray, and you’ll stay for observation before heading home. During that time, the care team keeps an eye on things like blood pressure and watches for temporary side effects, such as dizziness or feeling disconnected from your surroundings.
IV ketamine follows a different routine. Rather than using a nasal spray, the medication is delivered through an IV infusion. Appointments are usually longer, and you’ll also spend time being monitored before you’re cleared to leave.
For many people, those practical differences matter just as much as the medication itself. Knowing how long appointments take, what recovery looks like afterward, and whether you’ll need someone to drive you home can all influence which treatment feels more manageable.
How Do Doctors Decide Between Spravato and Ketamine?
Choosing a treatment usually involves far more than comparing two medications.
A psychiatrist first wants to understand what has already been tried. Have multiple antidepressants failed? Are the depressive symptoms becoming more severe? Is the diagnosis major depression, or is something else contributing?
Those answers shape the recommendation.
Spravato is approved as a treatment for depression in adults with treatment-resistant depression when combined with an oral antidepressant. It also has an indication for adults experiencing suicidal ideation associated with major depression, provided treatment takes place within appropriate medical care.
Practical questions matter, too.
Many patients ask about insurance coverage before anything else. Because Spravato has FDA-approved indications, treatment may be covered by insurance for eligible patients. Coverage for off-label ketamine treatments can be less predictable, so it’s worth verifying benefits before starting care.
How Can Scottsdale TMS Help?
After reading about Spravato vs ketamine, it’s easy to walk away thinking you need to choose between two competing treatments.
In reality, that’s rarely how good mental health care works.
At Scottsdale TMS, the first conversation isn’t about picking a medication. It’s about understanding why previous treatments haven’t worked, what’s happening today, and which evidence-based option makes the most sense moving forward. For some people, that may include Spravato. For others, another approach may be more appropriate.
The goal isn’t to steer every patient toward the same treatment.
It’s to recommend the one that fits the person sitting in front of the clinician.